# Study to Evaluate the Efficacy, Safety and Pharmacokinetics of PT001, PT003, and PT005 Following Chronic Dosing (7 Days) in Patients With Moderate to Very Severe Chronic Obstructive Pulmonary Disease (COPD)

> **NCT01085045** · PHASE2 · COMPLETED · sponsor: **Pearl Therapeutics, Inc.** · enrollment: 118 (actual)

## Conditions studied

- Chronic Obstructive Pulmonary Disease

## Interventions

- **DRUG:** PT003 MDI
- **DRUG:** PT005 MDI
- **DRUG:** Placebo MDI
- **DRUG:** Tiotropium bromide 18 μg (Spiriva Handihaler®)
- **DRUG:** Formoterol Fumarate 12 μg (Foradil® Aerolizer®)
- **DRUG:** PT001 MDI

## Key facts

- **NCT ID:** NCT01085045
- **Lead sponsor:** Pearl Therapeutics, Inc.
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE2
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2010-03
- **Primary completion:** 2010-11
- **Final completion:** 2010-11
- **Target enrollment:** 118 (ACTUAL)
- **Last updated:** 2017-04-26


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT01085045

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT01085045, "Study to Evaluate the Efficacy, Safety and Pharmacokinetics of PT001, PT003, and PT005 Following Chronic Dosing (7 Days) in Patients With Moderate to Very Severe Chronic Obstructive Pulmonary Disease (COPD)". Retrieved via AI Analytics 2026-06-01 from https://api.ai-analytics.org/clinical/NCT01085045. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*